Clinical Trials Logo

Clinical Trial Summary

The main goal of this study is to collect post marketing data from patients with chronic hepatitis D virus (HDV) infection who are treated with bulevirtide to describe the long-term effects of bulevirtide treatment and evaluate the safety of participants treated with bulevirtide.


Clinical Trial Description

The study design time perspective is retrospective and prospective for participants who previously participated in MYR-Reg-02 and are currently receiving BLV and prospective for participants who are scheduled to receive BLV. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05718700
Study type Observational [Patient Registry]
Source Gilead Sciences
Contact Gilead Clinical Study Information Center
Phone 1-833-445-3230 (GILEAD-0)
Email GileadClinicalTrials@gilead.com
Status Recruiting
Phase
Start date February 7, 2023
Completion date November 2027

See also
  Status Clinical Trial Phase
Completed NCT05827146 - Study of Hepalatide in Chronic Hepatitis D(CHD) Patients Phase 2
Completed NCT02430181 - Lonafarnib With and Without Ritonavir in HDV (LOWR-1) Phase 2
Recruiting NCT05765344 - Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function Phase 1
Recruiting NCT05760300 - A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function Phase 1
Recruiting NCT06248580 - Find HDV and Determine Its Status in Turkey
Completed NCT02637999 - Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection Phase 1/Phase 2
Recruiting NCT04638439 - The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection Phase 1
Completed NCT02430194 - Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2) Phase 2